RecruitingSolid Tumors
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Sponsor: Exelixis
Where it's recruiting
Arkansas
Rogers
California
Los Angeles
District of Columbia
Washington D.C.
Florida
Orlando
Michigan
Grand Rapids
New Jersey
New Brunswick
North Carolina
Huntersville
Texas
Houston · San Antonio
Source: ClinicalTrials.gov · NCT07123103 · last updated 2026-02-17